Immunomodulatory therapies delay disease progression in multiple sclerosis

Roberto Bergamaschi, Silvana Quaglini, Eleonora Tavazzi, Maria Pia Amato, Damiano Paolicelli, Valentina Zipoli, Alfredo Romani, Carla Tortorella, Emilio Portaccio, Mariangela D'Onghia, Francesca Garberi, Valeria Bargiggia, Maria Trojano

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs (DMDs). Objective: Assessment of the efficacy of DMDs on long-term evolution of multiple sclerosis, using a Bayesian approach to overcome methodological problems related to open-label studies. Methods: MS patients from three different Italian multiple sclerosis centres were divided into subgroups according to the presence of treatment in their disease history before the endpoint, which was represented by secondary progression. Patients were stratified on the basis of the risk score BREMS (Bayesian risk estimate for multiple sclerosis), which is able to predict the unfavourable long-term evolution of MS at an early stage. Results: We analysed data from 1178 patients with a relapsing form of multiple sclerosis at onset and at least 10 years of disease duration, treated (59%) or untreated with DMDs. The risk of secondary progression was significantly lower in patients treated with DMDs, regardless of the initial prognosis predicted by BREMS. Conclusions: DMDs significantly reduce the risk of multiple sclerosis progression both in patients with initial high-risk and patients with initial low-risk. These findings reinforce the role of DMDs in modifying the natural course of the disease, suggesting that they have a positive effect not only on the inflammatory but also on the neurodegenerative process. The study also confirms the capability of the BREMS score to predict MS evolution.

Original languageEnglish
Pages (from-to)1732-1740
Number of pages9
JournalMultiple Sclerosis
Volume22
Issue number13
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Immunomodulation
Multiple Sclerosis
Disease Progression
Pharmaceutical Preparations
Bayes Theorem

Keywords

  • Bayesian analysis
  • clinical research methods
  • disease progression
  • immune therapies
  • Multiple sclerosis
  • prognosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., ... Trojano, M. (2016). Immunomodulatory therapies delay disease progression in multiple sclerosis. Multiple Sclerosis, 22(13), 1732-1740. https://doi.org/10.1177/1352458512445941

Immunomodulatory therapies delay disease progression in multiple sclerosis. / Bergamaschi, Roberto; Quaglini, Silvana; Tavazzi, Eleonora; Amato, Maria Pia; Paolicelli, Damiano; Zipoli, Valentina; Romani, Alfredo; Tortorella, Carla; Portaccio, Emilio; D'Onghia, Mariangela; Garberi, Francesca; Bargiggia, Valeria; Trojano, Maria.

In: Multiple Sclerosis, Vol. 22, No. 13, 01.11.2016, p. 1732-1740.

Research output: Contribution to journalArticle

Bergamaschi, R, Quaglini, S, Tavazzi, E, Amato, MP, Paolicelli, D, Zipoli, V, Romani, A, Tortorella, C, Portaccio, E, D'Onghia, M, Garberi, F, Bargiggia, V & Trojano, M 2016, 'Immunomodulatory therapies delay disease progression in multiple sclerosis', Multiple Sclerosis, vol. 22, no. 13, pp. 1732-1740. https://doi.org/10.1177/1352458512445941
Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, Zipoli V et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Multiple Sclerosis. 2016 Nov 1;22(13):1732-1740. https://doi.org/10.1177/1352458512445941
Bergamaschi, Roberto ; Quaglini, Silvana ; Tavazzi, Eleonora ; Amato, Maria Pia ; Paolicelli, Damiano ; Zipoli, Valentina ; Romani, Alfredo ; Tortorella, Carla ; Portaccio, Emilio ; D'Onghia, Mariangela ; Garberi, Francesca ; Bargiggia, Valeria ; Trojano, Maria. / Immunomodulatory therapies delay disease progression in multiple sclerosis. In: Multiple Sclerosis. 2016 ; Vol. 22, No. 13. pp. 1732-1740.
@article{c058d01ee50546ebacbddf9d4a97166c,
title = "Immunomodulatory therapies delay disease progression in multiple sclerosis",
abstract = "Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs (DMDs). Objective: Assessment of the efficacy of DMDs on long-term evolution of multiple sclerosis, using a Bayesian approach to overcome methodological problems related to open-label studies. Methods: MS patients from three different Italian multiple sclerosis centres were divided into subgroups according to the presence of treatment in their disease history before the endpoint, which was represented by secondary progression. Patients were stratified on the basis of the risk score BREMS (Bayesian risk estimate for multiple sclerosis), which is able to predict the unfavourable long-term evolution of MS at an early stage. Results: We analysed data from 1178 patients with a relapsing form of multiple sclerosis at onset and at least 10 years of disease duration, treated (59{\%}) or untreated with DMDs. The risk of secondary progression was significantly lower in patients treated with DMDs, regardless of the initial prognosis predicted by BREMS. Conclusions: DMDs significantly reduce the risk of multiple sclerosis progression both in patients with initial high-risk and patients with initial low-risk. These findings reinforce the role of DMDs in modifying the natural course of the disease, suggesting that they have a positive effect not only on the inflammatory but also on the neurodegenerative process. The study also confirms the capability of the BREMS score to predict MS evolution.",
keywords = "Bayesian analysis, clinical research methods, disease progression, immune therapies, Multiple sclerosis, prognosis",
author = "Roberto Bergamaschi and Silvana Quaglini and Eleonora Tavazzi and Amato, {Maria Pia} and Damiano Paolicelli and Valentina Zipoli and Alfredo Romani and Carla Tortorella and Emilio Portaccio and Mariangela D'Onghia and Francesca Garberi and Valeria Bargiggia and Maria Trojano",
year = "2016",
month = "11",
day = "1",
doi = "10.1177/1352458512445941",
language = "English",
volume = "22",
pages = "1732--1740",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "13",

}

TY - JOUR

T1 - Immunomodulatory therapies delay disease progression in multiple sclerosis

AU - Bergamaschi, Roberto

AU - Quaglini, Silvana

AU - Tavazzi, Eleonora

AU - Amato, Maria Pia

AU - Paolicelli, Damiano

AU - Zipoli, Valentina

AU - Romani, Alfredo

AU - Tortorella, Carla

AU - Portaccio, Emilio

AU - D'Onghia, Mariangela

AU - Garberi, Francesca

AU - Bargiggia, Valeria

AU - Trojano, Maria

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs (DMDs). Objective: Assessment of the efficacy of DMDs on long-term evolution of multiple sclerosis, using a Bayesian approach to overcome methodological problems related to open-label studies. Methods: MS patients from three different Italian multiple sclerosis centres were divided into subgroups according to the presence of treatment in their disease history before the endpoint, which was represented by secondary progression. Patients were stratified on the basis of the risk score BREMS (Bayesian risk estimate for multiple sclerosis), which is able to predict the unfavourable long-term evolution of MS at an early stage. Results: We analysed data from 1178 patients with a relapsing form of multiple sclerosis at onset and at least 10 years of disease duration, treated (59%) or untreated with DMDs. The risk of secondary progression was significantly lower in patients treated with DMDs, regardless of the initial prognosis predicted by BREMS. Conclusions: DMDs significantly reduce the risk of multiple sclerosis progression both in patients with initial high-risk and patients with initial low-risk. These findings reinforce the role of DMDs in modifying the natural course of the disease, suggesting that they have a positive effect not only on the inflammatory but also on the neurodegenerative process. The study also confirms the capability of the BREMS score to predict MS evolution.

AB - Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs (DMDs). Objective: Assessment of the efficacy of DMDs on long-term evolution of multiple sclerosis, using a Bayesian approach to overcome methodological problems related to open-label studies. Methods: MS patients from three different Italian multiple sclerosis centres were divided into subgroups according to the presence of treatment in their disease history before the endpoint, which was represented by secondary progression. Patients were stratified on the basis of the risk score BREMS (Bayesian risk estimate for multiple sclerosis), which is able to predict the unfavourable long-term evolution of MS at an early stage. Results: We analysed data from 1178 patients with a relapsing form of multiple sclerosis at onset and at least 10 years of disease duration, treated (59%) or untreated with DMDs. The risk of secondary progression was significantly lower in patients treated with DMDs, regardless of the initial prognosis predicted by BREMS. Conclusions: DMDs significantly reduce the risk of multiple sclerosis progression both in patients with initial high-risk and patients with initial low-risk. These findings reinforce the role of DMDs in modifying the natural course of the disease, suggesting that they have a positive effect not only on the inflammatory but also on the neurodegenerative process. The study also confirms the capability of the BREMS score to predict MS evolution.

KW - Bayesian analysis

KW - clinical research methods

KW - disease progression

KW - immune therapies

KW - Multiple sclerosis

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=84994634473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994634473&partnerID=8YFLogxK

U2 - 10.1177/1352458512445941

DO - 10.1177/1352458512445941

M3 - Article

AN - SCOPUS:84994634473

VL - 22

SP - 1732

EP - 1740

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 13

ER -